Masimo (NASDAQ:MASI) Stock Rating Lowered by Wolfe Research

Masimo (NASDAQ:MASI) was downgraded by equities researchers at Wolfe Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

Several other equities research analysts also recently weighed in on the company. Zacks Research downgraded Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Piper Sandler cut Masimo from an “overweight” rating to a “hold” rating and set a $180.00 price objective for the company. in a report on Tuesday. Weiss Ratings reissued a “sell (d)” rating on shares of Masimo in a report on Thursday, January 22nd. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Monday, December 1st. Finally, Wells Fargo & Company downgraded shares of Masimo from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $190.00 to $180.00 in a report on Wednesday. One investment analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Masimo has a consensus rating of “Hold” and a consensus price target of $181.17.

Masimo Trading Down 0.1%

MASI opened at $175.10 on Thursday. The business has a fifty day moving average price of $139.13 and a 200 day moving average price of $143.16. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.84 and a quick ratio of 1.92. The stock has a market capitalization of $9.40 billion, a price-to-earnings ratio of -16.61, a PEG ratio of 1.78 and a beta of 1.26. Masimo has a 12 month low of $125.94 and a 12 month high of $194.88.

Hedge Funds Weigh In On Masimo

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. MAI Capital Management boosted its position in shares of Masimo by 176.7% in the 2nd quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 129 shares during the period. Global Retirement Partners LLC acquired a new position in Masimo during the fourth quarter worth $27,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Masimo during the 4th quarter worth about $28,000. Los Angeles Capital Management LLC acquired a new position in Masimo during the fourth quarter valued at approximately $31,000. Finally, Rothschild Investment LLC increased its stake in shares of Masimo by 12,950.0% in the fourth quarter. Rothschild Investment LLC now owns 261 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 259 shares during the period. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.